Exelixis Inc
(NAS:EXEL)
$
35.81
-0.04 (-0.11%)
Market Cap: 10.23 Bil
Enterprise Value: 9.24 Bil
PE Ratio: 22.96
PB Ratio: 4.50
GF Score: 91/100 
Exelixis Inc at Barclays Global Healthcare Conference Transcript
Mar 13, 2019 / 01:30PM GMT
Release Date Price:
$24.71
(+4.75%)
Geoffrey Christopher Meacham
Barclays Bank PLC, Research Division - MD & Senior Research Analyst
Welcome to the second day of the Barclays Global Healthcare Conference. My name is Geoff Meacham, I'm the biopharma analyst here. My team here, too, I have Rick Harrison up on the stage with me and we're really excited to have Exelixis doing the fireside chat, and Mike Morrissey, CEO. Mike?
Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director
Good morning. Thanks for the -- well, thanks for the invite, great to be here. Yes.
Questions & Answers
Geoffrey Christopher Meacham
Barclays Bank PLC, Research Division - MD & Senior Research Analyst
So the -- I guess, let's just start with the core franchise cabozantinib has been a real success and maybe just give us, kind of, your high-level view of kind of how we got here? And kind of your general view going forward?
Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director
Okay.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers